CV-6209-d5 contains five deuterium atoms at the 1, 1, 2, 2, and 2 positions of the ethyl pyridinium moiety. It is intended for use as an internal standard for the quantification of CV-6209 by GC- or LC-mass spectrometry. CV-6209 is a potent antagonist of the platelet-activating factor (PAF) receptor, inhibiting aggregation of rabbit and human platelets induced by PAF with IC50 values of 75 and 170 nM, respectively.1 It has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen.1 CV-6209 is bioavailable, as it prevents PAF-induced hypotension in rats, while not blocking hypotension triggered by arachidonic acid , histamine, bradykinin , or isoproterenol .1 CV-6209 is used to study the role of PAF receptor signaling in vitro and in vivo.2,3
1.Terashita, Z., Imura, Y., Takatani, M., et al.CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivoJournal of Pharmacology and Experimental Therapeutics242263-268(1987) 2.Leong, H.S., Mahesh, B.M., Day, J.R., et al.Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factorJournal of Leukocyte Biology83(2)263-271(2008) 3.Musio, S., Pedotti, P., Mantegazza, R., et al.Anaphylaxis to a self-peptide in the absence of mast cells or histamineLaboratory Investigation89(4)398-405(2009)